Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Cancer Immunotherapy Reaches A Tipping Point

Oct 22 2014

• By Deborah Erickson

Related Content

Safety Profile Of Merck’s Anti-PD-1 Keytruda Shines In FDA Labeling

Sep 05 2014

Related Companies

Bristol Myers Squibb Company

Merck & Co., Inc.

AstraZeneca PLC

MedImmune LLC

Roche Holding AG

Bristol Myers Squibb Company

Memorial Sloan Kettering Cancer Center

Fred Hutchinson Cancer Research Center

Novartis AG

ARMO BioSciences, Inc.

Dendreon Corporation

Vertex Pharmaceuticals Incorporated

Gilead Sciences, Inc.

Genentech, Inc.

Novartis AG

Annias Immunotherapeutics, Inc.

Duke University School of Medicine

SELLAS Life Sciences Group, Inc.

Additional Topics

BioPharmaceutical

More from Archive

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window